Cargando…

Patients with metastatic renal cell carcinoma who receive immune-targeted therapy may derive survival benefit from nephrectomy

BACKGROUND: Nephrectomy, whether in the era of cytokine therapy or targeted therapy, has an important role in the treatment of metastatic renal cell carcinoma. With the advent of immunotherapy, immunotherapy combined with targeted therapy has become the mainstream of systemic therapy, but the role o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Hanzhi, Cao, Yuan, Jian, Yan, Lei, Jun, Zhou, Weimin, Yu, Xiaoling, Zhang, Xiquan, Peng, Zhiqiang, Sun, Zhe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557339/ https://www.ncbi.nlm.nih.gov/pubmed/37803307 http://dx.doi.org/10.1186/s12885-023-11408-x

Ejemplares similares

Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer
por: Russo, Paul, et al.
Publicado: (2007)

The impact of cytoreductive nephrectomy on survival outcomes in patients with metastatic renal cell carcinoma receiving immunotherapy: An evidence-based analysis of comparative outcomes
por: Li, Kun-peng, et al.
Publicado: (2023)

The impact of histology on survival for patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy
por: Carrasco, Alonso, et al.
Publicado: (2014)

Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Con
por: Kuusk, Teele, et al.
Publicado: (2022)

Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Pro
por: Campbell, Steven C., et al.
Publicado: (2022)

Partial Nephrectomy for Metastatic Renal Cell Carcinoma: Referee
por: Minervini, Andrea, et al.
Publicado: (2022)

Impact of Cytoreductive Nephrectomy on Survival in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy
por: Song, Yan, et al.
Publicado: (2016)

Cytoreductive nephrectomy for metastatic renal cell carcinoma: inequities in access exist despite improved survival
por: Patel, Manish I., et al.
Publicado: (2017)

Survival Outcomes Associated With Cytoreductive Nephrectomy in Patients With Metastatic Clear Cell Renal Cell Carcinoma
por: Chakiryan, Nicholas H., et al.
Publicado: (2022)

Metastatic renal cell carcinoma patients of T4 stage who are in status of N1 stage or older than 76 years cannot benefit from cytoreductive nephrectomy
por: Zhang, Zhao, et al.
Publicado: (2020)

The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases
por: Zhao, Zhijian, et al.
Publicado: (2019)

Elevated preoperative neutrophil-to-lymphocyte ratio may be associated with decreased overall survival in patients with metastatic clear cell renal cell carcinoma undergoing cytoreductive nephrectomy
por: Baum, Yoram S., et al.
Publicado: (2016)

The current role of cytoreductive nephrectomy for metastatic renal cell carcinoma
por: Umbreit, Eric C., et al.
Publicado: (2021)

The Evolving Landscape of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma
por: Studentova, Hana, et al.
Publicado: (2023)

Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy
por: Hoeh, Benedikt, et al.
Publicado: (2022)

Immunotherapy Is Associated with a Survival Benefit in Patients Receiving Chemotherapy for Metastatic Pancreatic Cancer
por: Hue, Jonathan J., et al.
Publicado: (2021)

Adverse Effect of Lymph Node Dissection in Metastatic Renal Cell Cancer Patients Treated with Cytoreductive Nephrectomy: A Contemporary Analysis of Survival
por: Cao, Dalong, et al.
Publicado: (2019)

Metastatic Renal Cell Carcinoma to the Thyroid 23 Years After Nephrectomy()
por: Valdez, Carrie, et al.
Publicado: (2014)

Prognostic significance of pathologic nodal positivity in non-metastatic patients with renal cell carcinoma who underwent radical or partial nephrectomy
por: Kim, Sung Han, et al.
Publicado: (2021)

Partial nephrectomy for small renal tumors may prevent chronic kidney disease
por: Kumar, Rajeev
Publicado: (2008)

Comparison of prognosis between patients undergoing radical nephrectomy versus partial nephrectomy for renal cell carcinoma ≤7 cm T3aN0/xM0: Survival benefit is biased toward partial nephrectomy
por: Liu, Shiliang, et al.
Publicado: (2021)

Survival benefit stratification of partial nephrectomy versus non‐surgical treatment in elderly patients with T1a renal cell carcinoma
por: Tang, Yaxiong, et al.
Publicado: (2023)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Allograft nephrectomy vs. no nephrectomy for failed renal transplants
por: McDonald, Michelle
Publicado: (2023)

Partial nephrectomy for metastatic renal cell carcinoma: Where do we stand?
por: Shahait, Mohammed, et al.
Publicado: (2015)

Is Cytoreductive Nephrectomy Still a Standard of Care in Metastatic Renal Cell Carcinoma?
por: Renner, Alex, et al.
Publicado: (2019)

The Effect of Cytoreductive Partial Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma
por: Chen, Jiabi, et al.
Publicado: (2020)

Cytoreductive Nephrectomy and Metastatic Renal Cell Carcinoma: State of the Art and Future Perspectives
por: Napolitano, Luigi, et al.
Publicado: (2023)

Nephrectomy for Renal Hypertension
Publicado: (1943)

C-reactive protein in patients with advanced metastatic renal cell carcinoma: Usefulness in identifying patients most likely to benefit from initial nephrectomy
por: Ito, Hiroki, et al.
Publicado: (2012)

Infused Therapy and Survival in Older Patients Diagnosed with Metastatic Breast Cancer who Received Trastuzumab
por: Griffiths, Robert I, et al.
Publicado: (2011)

Re: Comparison of immediate vs. deferred cytoreductive nephrectomy in patients with synchronous metastatic renal cell carcinoma receiving sunitinib: the SURTIME randomized clinical trial
por: Minervini, Andrea, et al.
Publicado: (2019)

Comparison of upfront versus deferred cytoreductive nephrectomy in patients with metastatic renal cell carcinoma receiving systemic therapy: a systematic review and meta-analysis
por: Li, Kun-peng, et al.
Publicado: (2023)

C-Reactive Protein Levels and Survival Following Cytoreductive Nephrectomy in 118 Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib: A Retrospective Study
por: Xu, Wen-Hao, et al.
Publicado: (2019)

Identifying patients who may benefit from treatment
por: Abacı, Adnan
Publicado: (2018)

The safety and efficacy of sunitinib before planned nephrectomy in metastatic clear cell renal cancer
por: Powles, T., et al.
Publicado: (2011)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Cytoreductive Nephrectomy and Overall Survival of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy—Data from the National Renis Registry
por: Poprach, Alexandr, et al.
Publicado: (2020)

Impact of Radical Nephrectomy and Partial Nephrectomy on Actual Estimated Overall Survival Compared to Life Expectancy in Patients with Renal Cell Carcinoma
por: Hori, Shunta, et al.
Publicado: (2021)

Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial
por: Bex, A, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s7h57037kv9jsofe6sh1u47r7v